Ignite Creation Date:
2024-06-16 @ 11:48 AM
Last Modification Date:
2024-10-26 @ 3:30 PM
Study NCT ID:
NCT06427642
Status:
RECRUITING
Last Update Posted:
2024-05-24
First Post:
2024-05-13
Brief Title:
Efficacy Evaluation of UCB-MNCs in the Treatment of Refractory Neonatal Diseases
Sponsor:
Shandong Qilu Stem Cells Engineering Co Ltd
Organization:
Shandong Qilu Stem Cells Engineering Co Ltd
Study Overview
Official Title:
Efficacy Evaluation of Umbilical Cord Blood-derived Mononuclear Cells in the Treatment of Refractory Neonatal Diseases
Status:
RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Hypoxic-ischemic encephalopathy HIE bronchopulmonary dysplasia BPD short bowel syndrome SBS are refractory in clinical treatment Thus how to better prevent such diseases is currently a key research topic in the international field The use of cord blood-derived mononuclear cells may promote to save lives and improve patient outcomes
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None